Should we include connection domain mutations of HIV-1 reverse transcriptase in HIV resistance testing?

PLoS Medicine

Volumn 4, Issue 12, 2007, Pages 1858-1861

  Götte, Matthias ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; LAMIVUDINE; NEVIRAPINE; NUCLEOSIDE ANALOG; RIBONUCLEASE H; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; ZIDOVUDINE; REVERSE TRANSCRIPTASE, HUMAN IMMUNODEFICIENCY VIRUS 1; RNA DIRECTED DNA POLYMERASE;

CROSS RESISTANCE; DRUG RESISTANCE; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; PHENOTYPE; REVIEW; SITE DIRECTED MUTAGENESIS; VIRUS MUTATION; CHEMISTRY; DRUG ANTAGONISM; DRUG EFFECT; ENZYMOLOGY; GENETIC SCREENING; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; METABOLISM; MULTIDRUG RESISTANCE; MUTATION; NOTE; PATIENT SELECTION; PROTEIN TERTIARY STRUCTURE; TIME; TREATMENT OUTCOME; VIROLOGY; VIRUS LOAD;

DRUG RESISTANCE, MULTIPLE, VIRAL; GENETIC TESTING; GENOTYPE; HIV INFECTIONS; HIV REVERSE TRANSCRIPTASE; HIV-1; HUMANS; MUTATION; NEVIRAPINE; PATIENT SELECTION; PHENOTYPE; PROTEIN STRUCTURE, TERTIARY; REVERSE TRANSCRIPTASE INHIBITORS; TIME FACTORS; TREATMENT OUTCOME; VIRAL LOAD; ZIDOVUDINE;

EID: 38049007454     PISSN: 15491277     EISSN: 15491676     Source Type: Journal    
DOI: 10.1371/journal.pmed.0040346     Document Type: Review

References (25)

1. Hirsch MS, Brun-Vezinet F, Clotet B, Conway B, Kuritzkes DR, et al. (2003) Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel. Clin Infect Dis 37: 113-128.
2. Cingolani A, Antinori A, Rizzo MG, Murri R, Ammassari A, et al. (2002) Usefulness of monitoring HIV drug resistance and adherence in individuals failing highly active antiretroviral therapy: a randomized study (ARGENTA). AIDS 16: 369-379.
3. Baxter JD, Mayers DL, Wentworth DN, Neaton JD, Hoover ML, et al. (2000) A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. CPCRA 046 Study Team for the Terry Beirn Community Programs for Clinical Research on AIDS. AIDS 14: F83-F93.
4. Tural C, Ruiz L, Holtzer C, Schapiro J, Viciana P, et al. (2002) Clinical utility of HIV-1 genotyping and expert advice: the Havana trial. AIDS 16: 209-218.
5. Durant J, Clevenbergh P, Halfon P, Delgiudice P, Porsin S, et al. (1999) Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomised controlled trial. Lancet 353: 2195-2199.
6. Meynard JL, Vray M, Morand-Joubert L, Race E, Descamps D, et al. (2002) Phenotypic or genotypic resistance testing for choosing antiretroviral therapy after treatment failure: a randomized trial. AIDS 16: 727-736.
7. Zolopa AR, Lazzeroni LC, Rinehart A, Vezinet FB, Clavel F, et al. (2005) Accuracy, precision, and consistency of expert HIV type 1 genotype interpretation: an international comparison (The GUESS Study). Clin Infect Dis 41: 92-99.
8. Larder BA, Kemp SD, Harrigan PR (1995) Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy. Science 269: 696-699.
9. Huang H, Chopra R, Verdine GL, Harrison SC (1998) Structure of a covalently trapped catalytic complex of HIV-1 reverse transcriptase: implications for drug resistance. Science 282: 1669-1675.
10. Kohlstaedt LA, Wang J, Friedman JM, Rice PA, Steitz TA (1992) Crystal structure at 3.5 A resolution of HIV-1 reverse transcriptase complexed with an inhibitor. Science 256: 1783-1790.
11. Sarafianos SG, Das K, Ding J, Boyer PL, Hughes SH, et al. (1999) Touching the heart of HIV-1 drug resistance: the fingers close down on the dNTP at the polymerase active site. Chem Biol 6: R137-R146.
12. Ren J, Stammers DK (2005) HIV reverse transcriptase structures: designing new inhibitors and understanding mechanisms of drug resistance. Trends Pharmacol Sci 26: 4-7.
13. Gallego O, Corral A, de Mendoza C, Rodes B, Soriano V (2002) Prevalence of G333D/E in naive and pretreated HIV-infected patients. AIDS Res Hum Retroviruses 18: 857-860.
14. Kemp SD, Shi C, Bloor S, Harrigan PR, Mellors JW, et al. (1998) A novel polymorphism at codon 333 of human immunodeficiency virus type 1 reverse transcriptase can facilitate dual resistance to zidovudine and L-2′,3′-dideoxy-3′-thiacytidine. J Virol 72: 5093-5098.
15. Harrigan PR, Salim M, Stammers DK, Wynhoven B, Brumme ZL, et al. (2002) A mutation in the 3′ region of the human immunodeficiency virus type 1 reverse transcriptase (Y318F) associated with nonnucleoside reverse transcriptase inhibitor resistance. J Virol 76: 6836-6840.
16. Nikolenko GN, Delviks-Frankenberry KA, Palmer S, Maldarelli F, Fivash MJ Jr., et al. (2007) Mutations in the connection domain of HIV-1 reverse transcriptase increase 3′-azido-3′-deoxythymidine resistance. Proc Natl Acad Sci U S A 104: 317-322.
17. Nikolenko GN, Palmer S, Maldarelli F, Mellors JW, Coffin JM, et al. (2005) Mechanism for nucleoside analog-mediated abrogation of HIV-1 replication: balance between RNase H activity and nucleotide excision. Proc Natl Acad Sci U S A 102: 2093-2098.
18. Meyer PR, Matsuura SE, Mian AM, So AG, Scott WA (1999) A mechanism of AZT resistance: an increase in nucleotide-dependent primer unblocking by mutant HIV-1 reverse transcriptase. Mol Cell 4: 35-43.
19. Delviks-Frankenberry KA, Nikolenko GN, Barr R, Pathak VK (2007) Mutations in human immunodeficiency virus type 1 RNase H primer grip enhance 3′-azido-3′-deoxythymidine resistance. J Virol 81: 6837-6845.
20. Ntemgwa M, Wainberg MA, Oliveira M, Moisi D, Lalonde R, et al. (2007) Variations in reverse transcriptase and RNase H domain mutations in human immunodeficiency virus type 1 clinical isolates show divergent phenotypic resistance to zidovudine. Antimicrob Agents Chemother 51: 3861-3869.
21. Brehm JH, Koontz D, Meteer JD, Pathak V, Sluis-Cremer N, et al. (2007) Selection of mutations in the connection and RNase H domains of human immunodeficiency virus type 1 reverse transcriptase that increase resistance to 3′-azido-3′-dideoxythymidine. J Virol 81: 7852-7859.
22. Cane PA, Green H, Fearnhill E, Dunn D (2007) Identification of accessory mutations associated with high-level resistance in HIV-1 reverse transcriptase. AIDS 21: 447-455.
23. Roquebert B, Wirden M, Simon A, Deval J, Katlama C, et al. (2007) Relationship between mutations in HIV-1 RNase H domain and nucleoside reverse transcriptase inhibitors resistance mutations in naive and pre-treated HIV infected patients. J Med Virol 79: 207-211.
24. Yap SH, Sheen CW, Fahey J, Zanin M, Tyssen D, et al. (2007) N348I in the connection domain of HIV-1 reverse transcriptase confers zidovudine and nevirapine resistance. PLoS Med : e335. doi:10.1371/journal.pmed.0040335
25. Hachiya A, Kodama E, Sarafianos S, Schuckman M, Matsuoka M, et al. (2007) A novel mutation, N348I in HIV-1 reverse transcriptase induced by NRTI treatment, confers nevirapine resistance [abstract 593]. 14th Conference on Retroviruses and Opportunistic Infections; 25-28 February 2007; Los Angeles, California, United States of America. Available: http://www.retroconference.org/ 2007/Abstracts/28792.htm. Accessed 4 November 2007.